Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN, USA.
J Am Acad Orthop Surg. 2010 Feb;18(2):94-107. doi: 10.5435/00124635-201002000-00004.
The Ewing sarcoma family of tumors (ESFT) consists of a group of tumors characterized by morphologically similar round-cell neoplasm and by the presence of a common chromosomal translocation. Although rare, such tumors constitute the third most frequent primary sarcoma of bone after osteosarcoma and chondrosarcoma. ESFT most commonly affects young children and adolescents. Because most patients with clinically apparent localized disease at diagnosis may also have occult metastatic (ie, systemic) disease, multidrug chemotherapy as well as local disease control with surgery and/or radiation therapy are indicated for all patients. Despite marked improvements in survival during the past 40 years for patients with localized disease, lesser improvements have been seen in patients with metastatic or recurrent disease. A better understanding of the complex biology of ESFT may lead to the successful development of biologically targeted therapies. As the regulatory pathways responsible for transformation, growth, and metastasis of ESFT become more refined, the number of potential therapeutic targets will expand.
尤文氏肉瘤家族肿瘤(ESFT)由一组形态相似的圆形细胞肿瘤和共同染色体易位特征的肿瘤组成。虽然罕见,但此类肿瘤构成继骨肉瘤和软骨肉瘤之后的第三大常见原发性骨肉瘤。ESFT 最常影响幼儿和青少年。由于大多数诊断时具有临床明显局限性疾病的患者也可能存在隐匿性转移(即全身性)疾病,因此所有患者均需要多药化疗以及手术和/或放射治疗来控制局部疾病。尽管过去 40 年来,局限性疾病患者的生存率显著提高,但转移性或复发性疾病患者的生存率提高幅度较小。对 ESFT 复杂生物学的更好理解可能会导致成功开发出针对生物学的靶向治疗方法。随着负责 ESFT 转化、生长和转移的调节途径变得更加精细,潜在的治疗靶点数量将会增加。